

Variations in Definitions and Outcome Measures in Gastroesophageal Reflux Disease: A Systematic Review

Maartje M.J. Singendonk, MD,^a Anna J. Brink, BSc,^a Nina F. Steutel, MD,^{a,b} Faridi S. van Etten-Jamaludin,^c Michiel P. van Wijk, MD, PhD,^{a,d} Marc A. Benninga, MD, PhD,^a Merit M. Tabbers, MD, PhD^a

abstract

CONTEXT: Gastroesophageal reflux (GER) is defined as GER disease (GERD) when it leads to troublesome symptoms and/or complications. We hypothesized that definitions and outcome measures in randomized controlled trials (RCTs) on pediatric GERD would be heterogeneous.

OBJECTIVES: Systematically assess definitions and outcome measures in RCTs in this population.

DATA SOURCES: Data were obtained through Cochrane, Embase, Medline, and Pubmed databases.

STUDY SELECTION: We selected English-written therapeutic RCTs concerning GERD in children 0 to 18 years old.

DATA EXTRACTION: Data were tabulated and presented descriptively. Each individual parameter or set of parameters with unique criteria for interpretation was considered a single definition for GER(D). Quality was assessed by using the Delphi score.

RESULTS: A total of 2410 unique articles were found; 46 articles were included. Twenty-six (57%) studies defined GER by using 25 different definitions and investigated 25 different interventions. GERD was defined in 21 (46%) studies, all using a unique definition and investigating a total of 23 interventions. Respectively 87 and 61 different primary outcome measures were reported by the studies in GER and GERD. Eight (17%) studies did not report on side effects. Of the remaining 38 (83%) studies that did report on side effects, 18 (47%) included this as predefined outcome measure of which 4 (22%) as a primary outcome measure. Sixteen studies (35%) were of good methodological quality.

LIMITATIONS: Only English-written studies were included.

CONCLUSIONS: Inconsistency and heterogeneity exist in definitions and outcome measures used in RCTs on pediatric GER and GERD; therefore, we recommend the development of a core outcome set.



^aDepartment of Pediatric Gastroenterology and Nutrition, Emma Children's Hospital, Academic Medical Center, Amsterdam, Netherlands; ^bDepartment of Clinical Epidemiology, Biostatistics and Bioinformatics, and ^cMedical Library, Academic Medical Center, Amsterdam, Netherlands; and ^dDepartment of Pediatric Gastroenterology and Nutrition, VU Medical Center, Amsterdam, Netherlands

Dr Singendonk conceptualized and designed the study, coordinated and supervised data collection, reviewed the literature, and drafted the initial manuscript; Ms Brink reviewed the literature and drafted the initial manuscript; Ms van Etten-Jamaludin designed the data collection instrument and conducted the data collection;

To cite: Singendonk MMJ, Brink AJ, Steutel NF, et al. Variations in Definitions and Outcome Measures in Gastroesophageal Reflux Disease: A Systematic Review. *Pediatrics*. 2017;140(2):e20164166

Gastroesophageal reflux (GER) is a normal physiologic process occurring several times per day in healthy infants and children and is only referred to as GER disease (GERD) when it causes troublesome symptoms and/or complications.¹⁻⁴ Claim database analysis revealed that GERD accounts for 4% of all pediatric hospital admissions in the United States and costs ~\$750 million per year.^{5,6} The diagnosis of GERD is currently solely based on history taking and physical examination and may be relatively easy to establish when classic symptoms, such as regurgitation, vomiting, and irritability during or after feeds are accompanied by alarm symptoms such as hematemesis or failure to thrive. However, in most cases, no alarm symptoms are present (yet) and discerning GERD from physiologic GER can be difficult, especially in infants and young children.

A well-validated diagnostic tool for GERD would thus be extremely helpful. Despite the wide availability of diagnostic tests, including pH-(impedance) monitoring, endoscopy, and empirical acid-suppressive therapy, the diagnostic accuracy of these tests in children remains unclear.⁷ Although pH-impedance monitoring is considered the gold standard to diagnose GERD in adults and is recommended for the evaluation of GERD and its relation to symptoms in infants and children not responding to therapy, the lack of normative pediatric ranges hampers its application as a gold standard diagnostic in children.^{4,8} Factors contributing to the reflux burden in children have not yet been fully elucidated, leading to a wide variety in hypotheses and potential treatment strategies and inducing the potential of overtreatment despite a lack of symptom reduction and potential occurrence of side effects.⁹⁻¹²

Clinical trials that aim to determine the benefits and risks of interventions should measure outcomes that are important to patients and parents, and useful to health care professionals and policymakers alike. It can be difficult, however, to determine which outcomes are most important for a given condition and a given setting. Therefore, standardization of outcome measures for randomized controlled trials (RCTs) has been proposed.^{13,14} Such standardized outcome measures are not available for children with GERD. A first step in this procedure is to review the definitions and outcome measures of GERD that are currently used in therapeutic RCTs. We therefore aimed to systematically review definitions and outcome measures used in therapeutic RCTs performed in infants and children with GERD. We hypothesize that these definitions and outcome measures are heterogeneous.

METHODS

Search Strategy

The databases Cochrane (Central), Embase, Medline, and PubMed were searched from inception to November 2015 (full search strategy and keywords shown in Supplemental Table 7). To identify additional studies, reference lists of relevant studies identified in the literature search were searched by hand. During the whole process the exact reporting guidelines as described in the Preferred Reporting Items for Systematic Reviews and Meta-Analysis statement were followed.

Study Selection

Two investigators (M.M.J.S. and A.J.B.) independently reviewed the titles and abstracts of all citations in the literature results. Possible relevant studies were retrieved for full-text review. Therapeutic (systematic

reviews of) RCTs in infants and children with GERD (age 0–18 years) were included if they were written in English and a definition of GERD was provided by the authors. Studies were excluded if the study arm was composed of <10 patients. This approach is justified by Turner et al,¹⁵ stating that if several large, high-quality studies have been found in the initial searches, searching can be truncated because the inclusion of more obscure, smaller studies would be unlikely to change conclusions of the review. Studies comparing 2 different kinds of 1 specific intervention, like dose-comparing studies, were also excluded, as we assumed that these studies would not evaluate the therapeutic effect of the intervention as their primary objective. Disagreements between reviewers were adjudicated by discussion and consensus (M.M.T.).

Data Extraction and Analysis

For each included trial, the definitions used to describe GERD and the primary outcomes regarding GERD were extracted. Data derived from included articles contained author and year of enrollment, study setting, methods, type of participants, method of GERD assessment, type of intervention, follow-up, predefined outcome measures, and results. Each individual parameter or set of parameters with unique criteria for interpretation was considered to be a single definition for GERD. Data extraction from studies in infants (age 0–12 months) was separated from the studies assessing both infants and children (ages 0–18 years).

Methodological quality of the included RCTs was assessed by using the Delphi List.¹⁶ The Delphi list was developed as a standardized list to assess the quality of RCTs. This scale ranges from 0 (minimum) to 10 (maximum). High quality was defined as a score of >6 points, an average

quality as a score 4 to 6, and a low quality as a score ≤ 3 .

RESULTS

Search Results

The search yielded 2410 potentially relevant articles. After deducting duplicates, 1533 unique titles and abstracts were screened for eligibility and 1418 studies were excluded as they were not relevant to our search question (ie, no [systematic review of] RCT, no definition of GERD provided, or the study was of an adult population). After the evaluation of the full text, an additional 72 articles were excluded for not meeting our inclusion criteria (ie, inappropriate study design [$n = 55$], <10 patients per study arm [$n = 16$], and lack of a clear definition of GER/GERD [$n = 1$]). Checking the bibliographies of the systematic reviews of RCTs resulted in 3 additional RCTs (Fig 1), resulting in a total of 46 included studies. These additional studies were not identified by the original search as they did not include any of the search terms for a RCT in their title or abstract.

Study and Patient Characteristics

In total, 2630 patients were included in 46 studies (26 studies in infants <12 months only and 20 studies in infants and children 0–18 years; there were no studies that only included children >12 months). The included studies that concerned both infants and children did not provide a breakdown based on age to describe the definitions of GERD, interventions, or outcome measures that were studied. For this reason, data regarding studies conducted in infants only and studies conducted in both infants and children are presented separately in the current study. The study characteristics are described in Supplemental Tables 8–12.




FIGURE 1

Prisma 2009 flow diagram. For more information, visit www.prisma-statement.org. (Reprinted with permission from Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group [2009]. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *PLoS Med*. 6[7]:e1000097.)

Definitions

In 26 studies, patients were included based on a definition of GER ($n = 16$ studies in infants only), and in 21 studies based on a definition of GERD ($n = 11$ studies in infants only). In one of these studies, both GER and GERD patients were included.¹⁷

GER ($n = 26$ Studies)

Between studies, 42 different criteria for interpretation of (combinations of) clinical and investigational parameters were used to define GER, resulting in 25 different definitions among studies (Table 1). Definitions of GER were based on clinical parameters only in 12 studies by using 12 different criteria for interpretation. GER was defined based on parameters from diagnostic investigations only in 7 studies using

6 different criteria for interpretation. The definition of GER was developed through a combination of both clinical and diagnostic parameters in 7 studies using 7 different criteria for interpretation. The majority of studies (13/16, 81%) based their definition of GER at least partly on clinical parameters, of which measures of regurgitation or vomiting frequency were most commonly used. The studies that concerned both infants and children based their definition of GER predominantly on pH-criteria (8/10, 80%), although the frequency of regurgitation or vomiting was only used in 2 (20%) of the studies. Twenty-five different interventions were assessed (Table 2; $n = 11$ different nonpharmacological interventions, $n = 11$ different

pharmacological interventions, $n = 3$ different combinations of nonpharmacological and pharmacological interventions). Those studies that were conducted in infants only regarded both pharmacological and nonpharmacological interventions, whereas studies that included both infants and children regarded the investigation of pharmacological interventions only.

GERD (n = 21 Studies)

The 21 studies that addressed GERD all used a unique definition by using a total of 41 different criteria for interpretation of (combinations of) clinical and investigational parameters (Table 3). Definitions were based on clinical parameters only in 11 studies, on investigational parameters resulting from diagnostic investigations only in 4 studies, and on a combination of both parameters in 6 studies. All studies that were conducted in infants only used at least 1 clinical parameter to define GERD; mostly by reporting measures of regurgitation or vomiting (5/11, 45%). Three studies (27%) additionally used at least 1 additional diagnostic intervention, of which pH monitoring was most commonly used (2/11, 18%). The majority of studies (7/10, 70%) conducted in both infants and children used at least 1 diagnostic intervention to define GERD, predominantly by using pH monitoring combined with multichannel intraluminal impedance monitoring (pH-MII) characteristics (4/10, 40%). Twenty-three different interventions were assessed (Table 4; $n = 4$ different nonpharmacological interventions, $n = 15$ different pharmacological interventions, $n = 4$ different combinations of nonpharmacological and pharmacological interventions). All studies predominantly studied a combination of pharmacological interventions (8/11 [82%] studies in infants only; 10/10 [100%] studies in both infants and children).

Primary Outcome Measures

GER (n = 26 Studies)

Eighty-seven different primary outcome measures were used in the 26 studies regarding interventions for GER (Table 5). Symptoms were used as primary outcome measure in 16 studies ($n = 23$ different outcome measures) and parameters from diagnostic investigations were used in 21 studies ($n = 62$ different outcome measures). Two studies used 2 different definitions of side effects as primary outcome measure. Eighteen studies evaluated the therapeutic effect on the basis of pH-MII parameters, mostly by using the reflux index (the percentage of time that the esophageal pH <4) and reporting the total number of reflux episodes. Clinical parameters and investigational parameters were equally used as outcome measures in those studies that concerned infants only (respectively 10/16, [63%] and 11/16 [69%] studies reported at least 1 parameter). Of the clinical parameters, measures of regurgitation or vomiting were predominantly used among studies that concerned infants only (6/16, 38%). In those studies regarding both infants and children, investigational parameters were predominantly reported as outcome measures (8/10, 80%); all studies used pH-characteristics.

GERD (n = 21 Studies)

Sixty-one different primary outcome measures were used in the 21 studies regarding interventions for GERD (Table 6). Individual clinical symptoms or composed scores of clinical symptoms were used as a primary outcome measure in 17 studies, resulting in 25 different outcome measures. Parameters resulting from at least 1 diagnostic investigation were used in 9 studies, resulting in 34 different outcome measures. Two studies used 2 different definitions of side effects as primary outcome measure.

Side Effects

Side effects were reported in 38 (83%) studies. Of these studies, 18 (47%) reported this as a predefined outcome measure, of which 4 (22%) studies included this as a primary outcome measure. In 8 (17%) studies there were no data on side effects reported. Four (9%) of these studies regarded pharmacological interventions.

Methodological Quality

The Delphi list was used to assess the methodological quality of the included RCTs (Supplemental Tables 7–16).¹⁶ Two studies (4%) had a score ≤ 3 , indicating a low methodological quality and 16 studies (35%) were of good methodological quality (score >6). The remaining 28 studies (61%) scored between 4 and 6, indicating average methodological quality. Lack of treatment allocation, unclear, and high or unclear drop-out rates were the most common reasons for reduced methodological quality.

DISCUSSION

This study is the first to systematically review definitions and outcome measures used in intervention trials on pediatric GERD and shows a lack of agreement on definitions, predefined outcome measures, and instruments used to evaluate GERD within these trials. We identified 46 RCTs by using 25 unique definitions of GER and 21 unique definitions of GERD. Respectively 87 and 61 different primary outcome measures were reported in studies on GER and GERD; the majority regarding individual or composed scores of clinical symptoms. The rationale for selecting outcome measures, and the measurement properties of the outcome measure tools (when used), were most often not reported.

The use of a uniform definition to describe a study population is

TABLE 1 Definitions Used for GER

No. of Trials	Definition	Infants (0–12 mo)										Infants and Children (0–18 y)															
		Beilissant et al. ¹⁸	Corvaglia et al. ¹⁹	Del Buono et al. ²⁰	Indrio et al. ²¹	Loots et al. ²²	Miller ²³	Moore et al. ²⁴	Moukarrzel et al. ²⁵	Ostrom et al. ²⁶	Tolia et al. ²⁷	Ummarino et al. ²⁸	Van Eygen and Van Ravenswaay ²⁹	Vandenplas et al. ³⁰	Vanderhoof et al. ³¹	Ximas et al. ³²	Buts et al. ³³	Carnuccio et al. ³⁴	Dothem et al. ³⁵	Cucchiara et al. ³⁶	Forbes et al. ³⁷	Greally et al. ³⁸	Levi et al. ³⁹	Levy et al. ⁴⁰	Scott et al. ⁴¹	Serra et al. ⁴²	
19	Clinical parameters (<i>n</i> = 29 different criteria for interpretation)																										
10	Regurgitation (<i>n</i> = 7 different criteria)	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
5	Frequency of regurgitation, cutoff documented	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
3	Frequency of regurgitation, no cutoff documented	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
5	Frequency of vomiting (<i>n</i> = 3 different criteria)	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
2	Crying (<i>n</i> = 2 different criteria)	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
2	Other symptoms (<i>n</i> = 4 different criteria)	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
2	Upper airway disorders	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
1	Heartburn	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
1	Failure to thrive	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
4	Symptoms related to feedings (<i>n</i> = 4 different criteria)	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
1	Suspicion of reflux (NFS, <i>n</i> = 1 criterion)	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
2	Rome III criteria	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
3	Composed scores of clinical symptoms (<i>n</i> = 3 different criteria)	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
2	HGERQ-R	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
1	Composed clinical score (by authors)	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
4	Failure to respond to nonpharmacological and pharmacological interventions (<i>n</i> = 4 different definitions)	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
14	Investigational parameters (<i>n</i> = 13 different criteria for interpretation)	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
14	Abnormal 24-h pH-metry results (<i>n</i> = 6 different criteria)	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
3	No. of reflux episodes (NFS)	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
3	Duration of single reflux episode	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
8	Percentage of time	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
2	Abnormal 24-h pH-metry results (NFS)	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
1	Abnormal gastric emptying results (<i>n</i> = 1 criterion)	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
1	Abnormal radiology results (<i>n</i> = 1 criterion)	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
2	Abnormal endoscopy results (<i>n</i> = 2 different criteria)	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
1	Abnormal fluoroscopy results (<i>n</i> = 1 criterion)	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X

Each individual parameter or set of parameters with unique criteria for interpretation was considered as a single definition for GERD. 24-h pH-metry, 24-hour esophageal pH monitoring; HGERQ-R, Infant Gastroesophageal Reflux Questionnaire Revised; NFS, not further specified.

^a Definitions of both GER and GERD provided.

^b Symptoms of vomiting, crying, and gagging were scored as follows: 0 = symptom absent, 1 = mild, 2 = moderate, and 3 = severe.

^c Intraepithelial eosinophils or >2 of the following: >20% basal cell layer thickness of total epithelial thickness, 60% papillary length of total epithelial thickness, >C20 lymphocytes in on high-power field.

^d With histology of esophageal mucosa.

important to obtain homogenous patient populations, allowing comparison between studies. Definitions for GERD applied in the included RCTs in this review varied widely, and none of the included trials used the exact definitions of the most recent European Society for Paediatric Gastroenterology, Hepatology, and Nutrition, North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition, and National Institute for Health and Care Excellence clinical guidelines for pediatric GERD.^{4,64} Surprisingly, between studies, the same parameters and cutoff values for interpretation were used by authors in their definitions of both GER and GERD. This finding importantly indicates that between studies, terminology may be used interchangeably and patients with similar clinical characteristics may as well be attributed physiologic *GER* or pathologic *GERD*.

Of the 46 included trials, 26 studies were performed in infants (of which only 1 study exclusively assessed newborns age <28 days) and 20 studies were performed in both infants and children. These studies neither provided a breakdown on age regarding definitions for GERD nor for interventions and outcome measures studied. As GERD symptoms are known to vary largely by age, different age groups may involve different treatment goals and measures to evaluate treatment efficacy. In the present review, we were limited to provide an overview of those studies conducted in infants only and studies conducted in a mixed population of both infants and children. We found that studies of only infants predominantly used a symptom-based definition of GERD and were also more likely to report symptom-based outcome measures. In contrast, studies conducted in a mixed population predominantly used measures obtained from diagnostic interventions to define

GERD and reported the effect of the studied interventions. Remarkably, in all these latter trials, the same definitions for GER(D) were applied to the whole study population, despite the difference in symptom presentation and clinical course of GER(D) symptoms between infants and children.^{65,66} Therefore, studies may inadvertently be examining a more heterogeneous population than expected. Not consistently including or standardizing presenting symptoms and complications of GERD as part of the disease definition consequently challenges the assessment of clinical symptoms and/or complications as an outcome measure. This limits generalizability and comparability of results across studies because the studies included patients with varying degrees of disease severity. Not adequately defining disease severity at the start of the study might also have a negative impact on the ability to detect change over time and success of a certain intervention. Although we did not assess the efficacy of treatment, for future studies it is important to realize that age at inclusion, as well as other factors such as prematurity and presence of comorbidity, could bias the treatment effect owing to the spontaneous improvement over time.

Most included studies did not use validated instruments to report on outcome measures, although for example in infants the Infant Gastroesophageal Reflux Questionnaire Revised has proved a reliable measure to assess symptoms over time and report on treatment outcome.⁶⁷ The lack of using a validated instrument to evaluate GERD and the heterogeneity of the present outcome measures make it complicated to interpret and compare study results. None of the studies included measures of parental or patient satisfaction or quality of life as one of their primary outcome measures. Previous research has

shown that perception of parents and health care professionals regarding the treatment of their infant can differ significantly.^{67,68} It is important to be aware of patient-related outcomes as they provide the cornerstone for family-centered care and parental satisfaction.

In a recent study, labeling an otherwise healthy infant with a GERD diagnosis increased parents' interest in medicating their infant, even when they were told that the medications were ineffective.⁶⁹ These findings suggest that a GERD label may influence parents' judgments by changing their assumptions about what kinds of interventions are considered most appropriate. This indicates that attitudes and perceptions of parents are an important consideration for clinicians when developing patient-tailored treatment strategies.

Side effects were used as a predefined outcome measure in only less than half of the studies and 8 studies did not report on this at all, of which 4 concerned studies assessing pharmacological interventions. Additionally, study duration ranged from 6 hours to 12 weeks, inducing the potential of missing relevant long-term side effects of treatment. This finding is of great importance, as the safety of long-term use of anti-reflux medication is currently under debate. However, at the same time, previous systematic reviews of GERD treatment suggest a paucity of high-quality evidence supporting acid-suppressive treatments for this condition.^{12,67,70} Forty-three percent of the trials included were from before the year 2000. This may reflect the limited number of studies that used the 2009 European Society for Paediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition definition of GERD, as well as the number of studies using instruments that were

TABLE 2 Interventions Used for GER

Interventions	No. of Trials	Source	
		Infants (0–12 mo)	Infants and Children (0–18 y)
Nonpharmacological interventions (<i>n</i> = 11 different interventions)	9		
Feed modification (<i>n</i> = 8 different interventions)	8		
Hydrolyzed formula	1	Corvaglia et al ¹⁹	—
Prethickened formula (NFS)	1	Moukarzel et al ²⁵	—
Formula thickened (rice starch)	1	Ummarino et al ²⁸	—
Formula thickened (cornstarch, casein predominant)	1	Xinias et al ³²	—
Formula thickened (Saint John's bread)	1	Vandenplas et al ⁵⁰	—
Soy-based formula	1	Ostrom et al ²⁶	—
Enfamil anti regurgitation formula (rice starch with lactose)	1	Vanderhoof et al ⁵¹	—
<i>Lactobacillus reuteri</i>	1	Indrio et al ²¹	—
Positioning therapy (<i>n</i> = 3 different interventions)	2		
Supine position during feedings	1	Corvaglia et al ¹⁹	—
Flat prone position during study period	1	Orenstein ¹⁷	—
Head-elevated prone position during study period	1	Orenstein ¹⁷	—
Massage therapy (<i>n</i> = 0 interventions)	0		
Pharmacological interventions (<i>n</i> = 11 different interventions)	20		
Antacids (<i>n</i> = 5 different interventions)	7		
Sodium alginate (gaviscon)	1	—	Buts et al ³³
Sodium and magnesium alginate (gaviscon infant)	3	Del Buono et al ²⁰ ; Miller ²³	Greally et al ³⁸
Magnesium hydroxide and aluminum hydroxide	1	—	Levi et al ³⁹
Alginate acid with antacid (gaviscon infant liquid)	1	—	Forbes et al ³⁷
Magnesium alginate aluminum-free formulation and simethicone	1	Ummarino et al ²⁸	—
Histamine 2 receptor antagonist (<i>n</i> = 1 intervention)	1		
Ranitidine	1	—	Cucchiara et al ³⁶
Prokinetics (<i>n</i> = 3 different interventions)	10		
Bethanechol	1	—	Levi et al ³⁹
Cisapride	6	Van Eygen and Van Ravensteyn ²⁹	Cohen et al ³⁵ ; Levy et al ⁴⁰ ; Scott et al ⁴¹ ; Greally et al ³⁸
Metoclopramide	3	Bellissant et al ¹⁸ ; Tolia et al ²⁷	Forbes et al ³⁷
PPI (<i>n</i> = 2 different interventions)	3		
Esomeprazole	1	Loots et al ²²	—
Omeprazole	3	Loots et al ²² ; Moore et al ²⁵	Cucchiara et al ³⁶
Combination of interventions (<i>n</i> = 3 different interventions)	2		
Head-elevated prone position to 30° during study period and increase in number of meals per day and general avoidance of excess fat in diet and addition of preparations of galactomannan, carboxidemethylcellulose or carob-seeds flour and sodic salt of alginate acid and a PPI (NFS)	1	—	Serra et al ⁴²
Domperidone and magnesium hydroxide and aluminum hydroxide	1	—	Carroccio et al ³⁴
Domperidone and alginate-antacid combination (NFS)	1	—	Carroccio et al ³⁴

Multiple interventions per study possible. NFS, not further specified; PPI, proton pump inhibitor; —, indicates not reported in this age-group.

developed only recently, such as pH-MII measurement and the Infant Gastroesophageal Reflux Questionnaire Revised.^{4,71} Although studies did not necessarily use the same diagnostic techniques to both define GERD and to evaluate treatment efficacy, the large variety of diagnostic techniques may however partly explain the lack of homogeneity in the definitions and outcome measures identified in the current study.

A limitation of our review may be that we chose English as the primary

language and it is possible that we could have missed RCTs published in other languages. To minimize the risk of other missed studies, we performed an extensive and sensitive literature search in collaboration with a clinical librarian. Another limitation may be that the Delphi list does not include all the items associated with the risk of bias, as it assigns weights to different items in the scale by providing an overall score per study. Additional assessment of items associated with bias would have been necessary

if it was our goal to use scores for eligibility criteria or to conduct subgroup analyses. The aim of the current study was however to provide overall assessment of the quality of the included trials, rather than performing a meta-analysis evaluating the efficacy of the different interventions.¹⁶

CONCLUSIONS

Many different definitions and outcome measures are used in intervention trials in pediatric

TABLE 3 Definitions Used for GERD

	Infants (0–12 mo)					Infants and Children (0–18 y)											
	Dresi et al ¹⁵	Davidson et al ¹⁴	Hussain et al ¹⁶	Lofts et al ¹⁷	Neu et al ¹⁸	Orenstein ¹⁷	Vandenplas et al ¹⁹	Witt et al ²⁰	Borrelli et al ²¹	Cucchiara et al ²²	Gustafsson et al ²³	Oderici et al ²⁴	Omani et al ²⁵	Drenstein et al ²⁶	Simeone et al ²⁷	Ummarino et al ²⁸	Zohalmezahad et al ²⁹
Clinical parameters (n = 26 different criteria for interpretation)																	
Frequency of regurgitation, no cutoff value documented (n = 1 criterion)			X														
Frequency of vomiting, no cutoff value documented (n = 3 different criteria)		X	X	X	X												X
Crying (n = 2 different criteria)		X	X	X	X												
Other symptoms (n = 5 different criteria)			X	X	X												
Upper airway disorders			X	X	X												
Failure to thrive			X	X	X												
Sleeping disturbance			X	X	X												
Experience of apparent life-threatening events		X	X	X	X												
Symptoms related to feedings (n = 2 different criteria)		X	X	X	X												
Quality of life (n = 1 criterion)																	X
Suspicion of reflux (NFS, n = 6 different criteria)		X	X	X	X												
Composed scores of clinical symptoms (n = 3 different criteria)																	
IGERQ-R																	
Composed clinical score (by authors)			X	X	X												
Failure to respond to nonpharmacological and pharmacological interventions (n = 3 different criteria)		X	X	X	X												X
Investigational parameters (n = 15 different criteria for interpretation)																	
Abnormal 24-h pH-metry results (n = 5 different criteria)																	
Percentage of time																	
Abnormal 24-h pH-metry results (NFS)																	
Abnormal pH-MII (n = 1 definition)																	X
Positive acid perfusion test (n = 1 criterion)																	
Abnormal endoscopy (n = 7 different criteria)																	
Abnormal fluorescence/lutite test (n = 1 criterion)																	

Each individual parameter or set of parameters with unique criteria for interpretation was considered a single definition for GERD. 24-h pH-metry, 24-hour esophageal pH monitoring, t-GERQ-R, Infant Gastroesophageal Reflux Questionnaire Revised; NFS, not further specified.

^a Authors provided a definition of GER as well as of GERD.

^b Definition of reflux esophagitis provided by authors.

^c Clinical score is a modified GERD Symptom Questionnaire in Infants.

^d >65% papillary height of the epithelial height, >20% basal cell thickness of the epithelial height, or polymorphonuclear leukocytes infiltrating in epithelium.

^e Grade 1 and 2 esophagitis on scale of Hetzel and Dent.

^f Histologic criteria according to Cucchiara et al.⁶³

TABLE 4 Interventions Used for GERD

Interventions	No. of Trials	Source	
		Infants (0–12 mo)	Infants and Children (0–18 y)
Nonpharmacological intervention (<i>n</i> = 4 different interventions)	3		
Feed modification (<i>n</i> = 0 interventions)	0		
Positioning therapy (<i>n</i> = 2 different interventions)	1		
Flat prone position during study period	1	Orenstein ¹⁷	—
Head-elevated prone position to 30° during study period	1	Orenstein ¹⁷	—
Massage therapy (<i>n</i> = 1 intervention)	2		
Moderate hand pressure on different places for 5 min, for a total duration of 30 min, twice a week	2	Neu et al ⁴⁸ ; Neu et al ⁴⁹	—
Other (<i>n</i> = 1 intervention)	1		
Quince syrup	1	—	Zohalinezhad et al ⁶²
Pharmacological intervention (<i>n</i> = 15 different interventions)	18		
Antacids (<i>n</i> = 3 different interventions)	3		
Magnesium hydroxide and aluminum hydroxide	1	—	Cucchiara et al ⁵⁴
Sodium alginate (gaviscon)	1	—	Borrelli et al ⁵³
Alginate-antacid combination (alginic acid, aluminum hydroxide, magnesium trisilicate, sodium bicarbonate)	1	—	Oderda et al ⁵⁷
Histamine 2 receptor antagonist (<i>n</i> = 4 different interventions)	7		
Cimetidine	2	—	Cucchiara et al ⁵⁴ ; Cucchiara et al ⁵⁵
Famotidine	1	—	Oderda et al ⁵⁷
Ranitidine	3	—	Ummarino et al ⁶¹ ; Gustafsson et al ⁵⁶ ; Orenstein et al ⁵⁹
Nizatidine	1	—	Simeone et al ⁶⁰
Prokinetics (<i>n</i> = 3 different interventions)	3		
Domperidone	1	Cresi et al ⁴³	—
Baclofen	1	—	Omari et al ⁵⁸
Cisapride	1	Vandenplas et al ⁵¹	—
Proton pump inhibitor (<i>n</i> = 5 different interventions)	7		
Esomeprazole	1	Davidson et al ⁴⁴	—
Lansoprazole	3	Orenstein et al ⁵⁰ ; Khoshoo et al ⁴⁶	Borrelli et al ⁵³
Omeprazole	1	—	Ummarino et al ⁶¹
Pantoprazole	1	Winter et al ⁵²	—
Rabeprazole	1	Hussain et al ⁴⁶	—
Combination of interventions (<i>n</i> = 4 different interventions)	1		
Esomeprazole and left-side positioning	1	Loots et al ⁴⁷	—
Esomeprazole and head-elevated prone position to 20°	1	Loots et al ⁴⁷	—
Aluminum hydroxide and magnesium hydroxide and simethicone (mylanta) and left-side positioning	1	Loots et al ⁴⁷	—
Aluminum hydroxide and magnesium hydroxide and simethicone (mylanta) and head-elevated prone position to 20°	1	Loots et al ⁴⁷	—

Multiple interventions per study possible. —, indicates not reported in this age-group.

GERD. Disagreement on the choice of outcome measures impedes a direct comparison of results on the efficacy of different interventions and has resulted in inconsistent reporting and the potential for reporting bias.^{72,73} Changing this situation will require a better understanding of what is normal and abnormal, which currently is hampered by the lack of a gold standard diagnostic tool.^{4,7}

There has been an increased awareness of the factors that

influence the quality of clinical trials in general and those in reflux disease in particular.^{74–76} Standardization of both definitions and outcomes in RCTs has been proposed as a solution to the problems of inappropriate and nonuniform outcome selection and reporting bias.^{13,14} As GERD is a symptom-driven disease, the primary outcome measures may well include the improvement of the cardinal symptom(s); either disappearance of a single symptom or its persistence at no more than a mild severity. As GERD symptoms are known to

vary widely by age and especially in infants, are often nonspecific and tend to disappear spontaneously with increasing age, a consensus of the definition of GERD in different age groups needs to be established first.^{4,77,78} The term “troublesome” as used by the current clinical guidelines recognizes the variability in how symptoms impact on individual patients and may well be used for this purpose.⁷⁶ GERD treatment includes both pharmacological and nonpharmacological interventions, which may be targeted to treat

TABLE 5 Primary Outcome Measures Used for GER

	Infants (0–12 mo)			Infants and Children (0–18 y)												
	Moore et al ¹⁸ et al ¹⁹ et al ²⁰	Indrio et al ²¹ et al ²²	Miller ²³ et al ²⁴ et al ²⁵	Ostrom et al ²⁶ et al ²⁷	Van Eygen and Van Ravensteyn ²⁸	Vanderplas et al ²⁹	Vanderhoof et al ³¹	Xinas et al ³² et al ³³	Carroccio et al ³⁴ et al ³⁵ et al ³⁶	Cohen et al ³⁷ et al ³⁸ et al ³⁹	Forbes et al ⁴⁰ et al ⁴¹ et al ⁴²	Grally et al ⁴³ et al ⁴⁴ et al ⁴⁵	Levi et al ⁴⁶ et al ⁴⁷ et al ⁴⁸	Orenstein et al ⁴⁹ et al ⁵⁰ et al ⁵¹	Scott et al ⁵² et al ⁵³ et al ⁵⁴	Serra et al ⁵⁵ et al ⁵⁶ et al ⁵⁷
Clinical parameters (n = 23 different primary outcomes)																
Regurgitation (n = 4 different primary outcomes)		X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Vomiting (n = 2 different primary outcomes)			X													
Crying (n = 2 different primary outcomes)				X												
Global clinical condition (n = 4 different primary outcomes)					X											
Symptoms related to feedings (n = 2 different primary outcomes)			X													
Other symptoms (n = 2 different primary outcomes)																
Nocturnal and morning asthma symptoms																
Composed scores of clinical symptoms (n = 5 different primary outcomes)																
I-GERQ score > 16			X													
Composed clinical score (by authors)				X												
Response to nonpharmacological and pharmacological intervention (n = 2 different primary outcomes)					X											X
Investigational parameters (n = 62 different primary outcomes)	21															
24-h pH-metry parameters (n = 20 different primary outcomes)	16															
No. of reflux episodes (n = 6 different primary outcomes)	13	X		X	X	X	X	X	X	X	X	X	X	X	X	X
Duration of reflux episodes (n = 5 different primary outcomes)	11		X	X	X	X	X	X	X	X	X	X	X	X	X	X
Reflux index (n = 3 different primary outcomes)	12	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Other (n = 6 different primary outcomes)	6			X	X	X	X	X	X	X	X	X	X	X	X	X
pH-MII parameters (n = 18 different primary outcomes)	3															
No. of reflux episodes (n = 6 different primary outcomes)	2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Duration of reflux episodes (n = 1 primary outcome)	2		X	X	X	X	X	X	X	X	X	X	X	X	X	X
Height of reflux episodes (n = 5 different primary outcomes)	2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Reflux index (n = 1 primary outcome)	2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Other (n = 5 different primary outcomes)	3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Gastric emptying time (n = 2 different primary outcomes)	2		X	X	X	X	X	X	X	X	X	X	X	X	X	X
Histologic parameters (n = 1 primary outcome)	1				X											
Pharmacokinetic evaluations (n = 11 different primary outcomes)	1															
ECG parameters (n = 3 different primary outcomes)	1															
Incidence of atologic manifestations (n = 1 primary outcome)	1															
Electrogastrography (n = 6 different primary outcomes)	1															
Side effects (n = 2 different primary outcomes)	2				X											

Multiple different outcome measures per study were possible. 24-h pH-metry, 24-hour esophageal pH monitoring, ECG, electrocardiogram, I-GERQ-R, Infant Gastroesophageal Reflux Questionnaire Revised.

^a Authors provided a definition of GER as well as of GERD.

TABLE 6 Primary Outcome Measures Used for GERD

	No. of Trials	Infants (0–12 mo)										Infants and Children (0–18 y)							
		Cressi et al ¹⁰	Davidson et al ⁴	Hussain et al ¹⁵	Khoshoo and Dhume ⁶	Loots et al ¹⁷	Neu et al ⁸	Neu et al ¹⁶	Orenstein et al ¹⁷	Vandenplas et al ¹¹	Winter et al ¹²	Borrelli et al ¹³	Cucchiara et al ¹⁴	Cucchiara et al ¹⁵	Bustafsson et al ¹⁶	Oderda et al ¹⁷	Orenstein et al ¹⁸	Simeone et al ¹⁹	Ummarmo Zohalnehzhad et al ²⁰
Clinical parameters (n = 25 different primary outcomes)	17																		
Regurgitation (n = 2 different primary outcomes)	3																		
Frequency of regurgitation	3			X															X
Vomiting (n = 0 primary outcomes)	0																		
Crying (n = 3 different primary outcomes)	2																		
Total crying time on treatment	1					X													
No. of crying episodes <1 h after feeding	1																		
Duration of crying episodes <1 h after feeding	1																		
Other symptoms (n = 5 different primary outcomes)	4																		
Nocturnal and morning asthma symptoms	1																		
Maternal-child interaction during feedings	1																		
Severity of GER symptoms (NIS)	2																		
Symptoms related to feedings (n = 0 primary outcomes)	0																		
Composed scores of clinical symptoms (n = 11 different primary outcomes)	13																		
I-GERQ-R (n = 4 different primary outcomes)	3			X															
Composed clinical score (by authors) (n = 7 different primary outcomes)	10		X	X		X													
Response to nonpharmacological and pharmacological intervention (n = 4 different primary outcomes)	3																		
Withdrawal rate because of lack of efficacy	1																		
Responder rate	2																		
Investigation parameters (n = 34 different primary outcomes)	9																		
24-h pH-metry parameters (n = 12 different primary outcomes)	6																		
No. of reflux episodes (n = 4 different primary outcomes)	2																		
Duration of reflux episodes (n = 3 different primary outcomes)	2																		
Reflux index (n = 1 primary outcome)	2																		
pH-MII parameters (n = 3 different primary outcomes)	4																		
No. of reflux episodes (n = 1 primary outcome)	1			X															
Duration of reflux episodes (n = 1 primary outcome)	1			X															
Reflux index (n = 0 primary outcomes)	0																		
Other (n = 1 primary outcome)	1																		
Histologic parameters (n = 3 primary outcomes)	4																		
Gastric emptying rate (n = 1 primary outcome)	1																		
Pharmacokinetic evaluations (n = 11 different primary outcomes)	1			X															
GERD-related signs (cardiorespiratory monitoring)	1																		
Spirometry (PEFR and FEV1)	1																		
Histamine challenge	1																		
Esophageal motility (pH-manometry)	1																		
Side effects (n = 2 different primary outcomes)	2																		

Multiple different outcome measures per study were possible. 24-h pH-metry, 24-hour esophageal pH monitoring, I-GERQ-R, Infant Gastroesophageal Reflux Questionnaire Revised.

^a Authors provided a definition of GER as well as of GERD.

^b Definition of reflux esophagitis.

different signs and symptoms accordingly. In addition to establishing a minimum core outcome set, establishing sets of proposed secondary outcome measures, depending on the object of the study as well as on the study population may well be appropriate. Therefore, to allow comparison between future studies, as a first step we recommend the development of both an infant- and a child-tailored

minimum core outcome set for clinical research in GERD by using the Delphi technique and early involvement of stakeholders.¹⁴ Embedding these core outcome sets within future clinical trials, systematic reviews, and clinical practice guidelines on pediatric GER(D) could make a profound contribution by advancing the usefulness of research to inform clinical practice, enhance patient

care, and improve clinical outcomes.

ABBREVIATIONS

GER: gastroesophageal reflux
GERD: gastroesophageal reflux disease
pH-MII: pH monitoring combined with multichannel intraluminal impedance monitoring

Drs Steutel, van Wijk, and Benninga conceptualized and designed the study and critically reviewed and revised the manuscript for important intellectual content; Dr Tabbers conceptualized and designed the study, coordinated and supervised data collection, and reviewed and revised the manuscript; and all authors have seen and approved the submission of this version of the manuscript and take full responsibility for the manuscript.

DOI: <https://doi.org/10.1542/peds.2016-4166>

Accepted for publication Apr 24, 2017

Address correspondence to M.M.J. Singendonk, MD, Department of Pediatric Gastroenterology and Nutrition, Emma Children's Hospital AMC, C2-312, PO Box 22700, 1100 DD Amsterdam, Netherlands. E-mail: m.m.j.singendonk@amc.uva.nl

PEDIATRICS (ISSN Numbers: Print, 0031-4005; Online, 1098-4275).

Copyright © 2017 by the American Academy of Pediatrics

FINANCIAL DISCLOSURE: The authors have indicated they have no financial relationships relevant to this article to disclose.

FUNDING: No external funding.

POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential conflicts of interest to disclose.

REFERENCES

1. Nelson SP, Chen EH, Syniar GM, Christoffel KK; Pediatric Practice Research Group. One-year follow-up of symptoms of gastroesophageal reflux during infancy. *Pediatrics*. 1998;102(6). Available at: www.pediatrics.org/cgi/content/full/102/6/e67
2. Nelson SP, Chen EH, Syniar GM, Christoffel KK; Pediatric Practice Research Group. Prevalence of symptoms of gastroesophageal reflux during childhood: a pediatric practice-based survey. *Arch Pediatr Adolesc Med*. 2000;154(2):150–154
3. Nelson SP, Kothari S, Wu EQ, Beaulieu N, McHale JM, Dabbous OH. Pediatric gastroesophageal reflux disease and acid-related conditions: trends in incidence of diagnosis and acid suppression therapy. *J Med Econ*. 2009;12(4):348–355
4. Vandenplas Y, Rudolph CD, Di Lorenzo C, et al; North American Society for Pediatric Gastroenterology and Hepatology and Nutrition; European Society for Pediatric Gastroenterology Hepatology and Nutrition. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). *J Pediatr Gastroenterol Nutr*. 2009;49(4):498–547
5. Gibbons TE, Stockwell J, Kreh RP, McRae S, Gold BD. Population based epidemiological survey of gastroesophageal reflux disease in hospitalized US children. *Gastroenterology*. 2001;120(5):A419
6. Canani RB, Cirillo P, Roggero P, et al; Working Group on Intestinal Infections of the Italian Society of Pediatric Gastroenterology, Hepatology and Nutrition (SIGENP). Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. *Pediatrics*. 2006;117(5). Available at: www.pediatrics.org/cgi/content/full/117/5/e817
7. van der Pol RJ, Smits MJ, Venmans L, Boluyt N, Benninga MA, Tabbers MM. Diagnostic accuracy of tests in pediatric gastroesophageal reflux disease. *J Pediatr*. 2013;162(5):983–987.e1
8. Singendonk MM, Benninga MA, van Wijk MP. Reflux monitoring in children. *Neurogastroenterol Motil*. 2016;28(10):1452–1459
9. Quitadamo P, Papadopoulou A, Wenzl T, et al. European pediatricians' approach to children with GER symptoms: survey of the implementation of 2009 NASPGHAN-ESPGHAN guidelines. *J Pediatr Gastroenterol Nutr*. 2014;58(4):505–509
10. Barron JJ, Tan H, Spalding J, Bakst AW, Singer J. Proton pump inhibitor utilization patterns in infants. *J Pediatr Gastroenterol Nutr*. 2007;45(4):421–427
11. van der Pol RJ, Smits MJ, van Wijk MP, Omari TI, Tabbers MM, Benninga MA.

- Efficacy of proton-pump inhibitors in children with gastroesophageal reflux disease: a systematic review. *Pediatrics*. 2011;127(5):925–935
12. van der Pol R, Langendam M, Benninga M, van Wijk M, Tabbers M. Efficacy and safety of histamine-2 receptor antagonists. *JAMA Pediatr*. 2014;168(10):947–954
 13. Sinha I, Jones L, Smyth RL, Williamson PR. A systematic review of studies that aim to determine which outcomes to measure in clinical trials in children. *PLoS Med*. 2008;5(4):e96
 14. Boers M, Kirwan JR, Wells G, et al. Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0. *J Clin Epidemiol*. 2014;67(7):745–753
 15. Turner RM, Bird SM, Higgins JP. The impact of study size on meta-analyses: examination of underpowered studies in Cochrane reviews. *PLoS One*. 2013;8(3):e59202
 16. Verhagen AP, de Vet HC, de Bie RA, et al. The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. *J Clin Epidemiol*. 1998;51(12):1235–1241
 17. Orenstein SR. Prone positioning in infant gastroesophageal reflux: is elevation of the head worth the trouble? *J Pediatr*. 1990;117(2 pt 1):184–187
 18. Bellissant E, Duhamel JF, Guillot M, Pariente-Khayat A, Olive G, Pons G. The triangular test to assess the efficacy of metoclopramide in gastroesophageal reflux. *Clin Pharmacol Ther*. 1997;61(3):377–384
 19. Corvaglia L, Mariani E, Aceti A, Galletti S, Faldella G. Extensively hydrolyzed protein formula reduces acid gastroesophageal reflux in symptomatic preterm infants. *Early Hum Dev*. 2013;89(7):453–455
 20. Del Buono R, Wenzl TG, Ball G, Keady S, Thomson M. Effect of Gaviscon Infant on gastro-oesophageal reflux in infants assessed by combined intraluminal impedance/pH. *Arch Dis Child*. 2005;90(5):460–463
 21. Indrio F, Riezzo G, Raimondi F, et al. Lactobacillus reuteri accelerates gastric emptying and improves regurgitation in infants. *Eur J Clin Invest*. 2011;41(4):417–422
 22. Loots CM, Wijnakker R, van Wijk MP, Davidson G, Benninga MA, Omari TI. Esophageal impedance baselines in infants before and after placebo and proton pump inhibitor therapy. *Neurogastroenterol Motil*. 2012;24(8):758–762, e351–e352
 23. Miller S. Comparison of the efficacy and safety of a new aluminium-free paediatric alginate preparation and placebo in infants with recurrent gastro-oesophageal reflux. *Curr Med Res Opin*. 1999;15(3):160–168
 24. Moore DJ, Tao BS, Lines DR, Hirte C, Heddl ML, Davidson GP. Double-blind placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux. *J Pediatr*. 2003;143(2):219–223
 25. Moukarzel AA, Abdelnour H, Akatcherian C. Effects of a prethickened formula on esophageal pH and gastric emptying of infants with GER. *J Clin Gastroenterol*. 2007;41(9):823–829
 26. Ostrom KM, Jacobs JR, Merritt RJ, Murray RD. Decreased regurgitation with a soy formula containing added soy fiber. *Clin Pediatr (Phila)*. 2006;45(1):29–36
 27. Tolia V, Galhoun J, Kuhns L, Kauffman RE. Randomized, prospective double-blind trial of metoclopramide and placebo for gastroesophageal reflux in infants. *J Pediatr*. 1989;115(1):141–145
 28. Ummarino D, Miele E, Martinelli M, et al. Effect of magnesium alginate plus simethicone on gastroesophageal reflux in infants. *J Pediatr Gastroenterol Nutr*. 2015;60(2):230–235
 29. Van Eygen M, Van Ravensteyn H. Effect of cisapride on excessive regurgitation in infants. *Clin Ther*. 1989;11(5):669–677
 30. Vandeplass Y, Hachimi-Idrissi S, Casteels A, Mahler T, Loeb H. A clinical trial with an “anti-regurgitation” formula. *Eur J Pediatr*. 1994;153(6):419–423
 31. Vanderhoof JA, Moran JR, Harris CL, Merkel KL, Orenstein SR. Efficacy of a pre-thickened infant formula: a multicenter, double-blind, randomized, placebo-controlled parallel group trial in 104 infants with symptomatic gastroesophageal reflux. *Clin Pediatr (Phila)*. 2003;42(6):483–495
 32. Xinias I, Mouane N, Le Luyer B, et al. Cornstarch thickened formula reduces oesophageal acid exposure in infants. *Dig Liver Dis*. 2005;37(1):23–27
 33. Buts JP, Barudi C, Otte JB. Double-blind controlled study on the efficacy of sodium alginate (Gaviscon) in reducing gastroesophageal reflux assessed by 24 h continuous pH monitoring in infants and children. *Eur J Pediatr*. 1987;146(2):156–158
 34. Carroccio A, Iacono G, Montalto G, Cavataio F, Soresi M, Notarbartolo A. Domperidone plus magnesium hydroxide and aluminum hydroxide: a valid therapy in children with gastroesophageal reflux. A double-blind randomized study versus placebo. *Scand J Gastroenterol*. 1994;29(4):300–304
 35. Cohen RC, O’Loughlin EV, Davidson GP, Moore DJ, Lawrence DM. Cisapride in the control of symptoms in infants with gastroesophageal reflux: a randomized, double-blind, placebo-controlled trial. *J Pediatr*. 1999;134(3):287–292
 36. Cucchiara S, Minella R, Iervolino C, et al. Omeprazole and high dose ranitidine in the treatment of refractory reflux oesophagitis. *Arch Dis Child*. 1993;69(6):655–659
 37. Forbes D, Hodgson M, Hill R. The effects of gaviscon and metoclopramide in gastroesophageal reflux in children. *J Pediatr Gastroenterol Nutr*. 1986;5(4):556–559
 38. Greally P, Hampton FJ, MacFadyen UM, Simpson H. Gaviscon and Carobel compared with cisapride in gastro-oesophageal reflux. *Arch Dis Child*. 1992;67(5):618–621
 39. Levi P, Marmo F, Saluzzo C, et al. Bethanechol versus antacids in the treatment of gastroesophageal reflux. *Helv Paediatr Acta*. 1985;40(5):349–359
 40. Levy J, Hayes C, Kern J, et al. Does cisapride influence cardiac rhythm? Results of a United States multicenter, double-blind, placebo-controlled pediatric study. *J Pediatr Gastroenterol Nutr*. 2001;32(4):458–463

41. Scott RB, Ferreira C, Smith L, et al. Cisapride in pediatric gastroesophageal reflux. *J Pediatr Gastroenterol Nutr.* 1997;25(5):499–506
42. Serra A, Cocuzza S, Poli G, La Mantia I, Messina A, Pavone P. Otologic findings in children with gastroesophageal reflux. *Int J Pediatr Otorhinolaryngol.* 2007;71(11):1693–1697
43. Cresi F, Marinaccio C, Russo MC, Miniero R, Silvestro L. Short-term effect of domperidone on gastroesophageal reflux in newborns assessed by combined intraluminal impedance and pH monitoring. *J Perinatol.* 2008;28(11):766–770
44. Davidson G, Wenzl TG, Thomson M, et al. Efficacy and safety of once-daily esomeprazole for the treatment of gastroesophageal reflux disease in neonatal patients. *J Pediatr.* 2013;163(3):692–698.e1
45. Hussain S, Kierkus J, Hu P, et al. Safety and efficacy of delayed release rabeprazole in 1- to 11-month-old infants with symptomatic GERD. *J Pediatr Gastroenterol Nutr.* 2014;58(2):226–236
46. Khoshoo V, Dhume P. Clinical response to 2 dosing regimens of lansoprazole in infants with gastroesophageal reflux. *J Pediatr Gastroenterol Nutr.* 2008;46(3):352–354
47. Loots C, Kritas S, van Wijk M, et al. Body positioning and medical therapy for infantile gastroesophageal reflux symptoms. *J Pediatr Gastroenterol Nutr.* 2014;59(2):237–243
48. Neu M, Pan Z, Workman R, Marcheggiani-Howard C, Furuta G, Laudenslager ML. Benefits of massage therapy for infants with symptoms of gastroesophageal reflux disease. *Biol Res Nurs.* 2014;16(4):387–397
49. Neu M, Schmiede SJ, Pan Z, et al. Interactions during feeding with mothers and their infants with symptoms of gastroesophageal reflux. *J Altern Complement Med.* 2014;20(6):493–499
50. Orenstein SR, Hassall E, Furmaga-Jablonska W, Atkinson S, Raanan M. Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. *J Pediatr.* 2009;154(4):514–520.e4
51. Vandenas Y, de Roy C, Sacre L. Cisapride decreases prolonged episodes of reflux in infants. *J Pediatr Gastroenterol Nutr.* 1991;12(1):44–47
52. Winter H, Kum-Nji P, Mahomedy SH, et al. Efficacy and safety of pantoprazole delayed-release granules for oral suspension in a placebo-controlled treatment-withdrawal study in infants 1-11 months old with symptomatic GERD. *J Pediatr Gastroenterol Nutr.* 2010;50(6):609–618
53. Borrelli O, Rea P, de Mesquita MB, et al. Efficacy of combined administration of an alginate formulation and lansoprazole for children with gastroesophageal reflux disease. *Ital J Pediatr.* 2002;28(4):304–309
54. Cucchiara S, Staiano A, Romaniello G, Capobianco S, Auricchio S. Antacids and cimetidine treatment for gastro-oesophageal reflux and peptic oesophagitis. *Arch Dis Child.* 1984;59(9):842–847
55. Cucchiara S, Gobio-Casali L, Balli F, et al. Cimetidine treatment of reflux esophagitis in children: an Italian multicentric study. *J Pediatr Gastroenterol Nutr.* 1989;8(2):150–156
56. Gustafsson PM, Kjellman NI, Tibbling L. A trial of ranitidine in asthmatic children and adolescents with or without pathological gastro-oesophageal reflux. *Eur Respir J.* 1992;5(2):201–206
57. Oderda G, Dell’Olio D, Forni M, Farina L, Tavassoli K, Ansaldi N. Treatment of childhood peptic oesophagitis with famotidine or alginate-antacid. *Ital J Gastroenterol.* 1990;22(6):346–349
58. Omari TI, Benninga MA, Sansom L, Butler RN, Dent J, Davidson GP. Effect of baclofen on esophagogastric motility and gastroesophageal reflux in children with gastroesophageal reflux disease: a randomized controlled trial. *J Pediatr.* 2006;149(4):468–474
59. Orenstein SR, Blumer JL, Faessel HM, et al. Ranitidine, 75 mg, over-the-counter dose: pharmacokinetic and pharmacodynamic effects in children with symptoms of gastro-oesophageal reflux. *Aliment Pharmacol Ther.* 2002;16(5):899–907
60. Simeone D, Caria MC, Miele E, Staiano A. Treatment of childhood peptic esophagitis: a double-blind placebo-controlled trial of nizatidine. *J Pediatr Gastroenterol Nutr.* 1997;25(1):51–55
61. Ummarino D, Miele E, Masi P, Tramontano A, Staiano A, Vandenas Y. Impact of antisecretory treatment on respiratory symptoms of gastroesophageal reflux disease in children. *Dis Esophagus.* 2012;25(8):671–677
62. Zohalinezhad ME, Imanieh MH, Samani SM, et al. Effects of Quince syrup on clinical symptoms of children with symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. *Complement Ther Clin Pract.* 2015;21(4):268–276
63. Cucchiara S, Minella R, D’Armiesto F, et al. Histologic grading of reflux oesophagitis and its relationship with intra-oesophageal and tragastric pH variables. *Eur J Gastroenterol Hepatol.* 1993;5(8):621–626
64. Davies I, Burman-Roy S, Murphy MS; Guideline Development Group. Gastro-oesophageal reflux disease in children: NICE guidance. *BMJ.* 2015;350:g7703
65. Winter HS. Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents. *UpToDate.* 2015. Available at: <https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-gastroesophageal-reflux-disease-in-children-and-adolescents>. Accessed November 1, 2015
66. Orenstein SR, Shalaby TM, Kelsey SF, Frankel E. Natural history of infant reflux esophagitis: symptoms and morphometric histology during one year without pharmacotherapy. *Am J Gastroenterol.* 2006;101(3):628–640
67. Latour JM, Hazelzet JA, Duivenvoorden HJ, van Goudoever JB. Perceptions of parents, nurses, and physicians on neonatal intensive care practices. *J Pediatr.* 2010;157(2):215–220.e3
68. Latour JM, van Goudoever JB, Duivenvoorden HJ, et al. Differences in the perceptions of parents and healthcare professionals on pediatric

- intensive care practices. *Pediatr Crit Care Med*. 2011;12(5):e211–e215
69. Scherer LD, Zikmund-Fisher BJ, Fagerlin A, Tarini BA. Influence of “GERD” label on parents’ decision to medicate infants. *Pediatrics*. 2013;131(5):839–845
 70. Chen I-L, Gao W-Y, Johnson AP, et al. Proton pump inhibitor use in infants: FDA reviewer experience. *J Pediatr Gastroenterol Nutr*. 2012;54(1):8–14
 71. Orenstein SR. Symptoms and reflux in infants: Infant Gastroesophageal Reflux Questionnaire Revised (I-GERQ-R)—utility for symptom tracking and diagnosis. *Curr Gastroenterol Rep*. 2010;12(6):431–436
 72. Sterne JAC, Egger M, Moher D. Addressing reporting biases. In: Higgins JPT, Green S, eds. *Cochrane Handbook for Systematic Reviews of Intervention Version 5.10*. London, United Kingdom: The Cochrane Collaboration; 2011
 73. Williamson P, Altman D, Blazeby J, Clarke M, Gargon E. Driving up the quality and relevance of research through the use of agreed core outcomes. *J Health Serv Res Policy*. 2012;17(1):1–2
 74. Altman DG, Schulz KF, Moher D, et al; CONSORT GROUP (Consolidated Standards of Reporting Trials). The revised CONSORT statement for reporting randomized trials: explanation and elaboration. *Ann Intern Med*. 2001;134(8):663–694
 75. Dent J, Kahrilas PJ, Vakil N, et al. Clinical trial design in adult reflux disease: a methodological workshop. *Aliment Pharmacol Ther*. 2008;28(1):107–126
 76. Moher D, Schulz KF, Altman D; CONSORT Group. The CONSORT Statement: revised recommendations for improving the quality of reports of parallel-group randomized trials 2001. *Explore (NY)*. 2005;1(1):40–45
 77. Sherman PM, Hassall E, Fagundes-Neto U, et al. A global, evidence-based consensus on the definition of gastroesophageal reflux disease in the pediatric population. *Arch Pediatr*. 2010;17(11):1586–1593
 78. Hegar B, Dewanti NR, Kadim M, Alatas S, Firmansyah A, Vandenplas Y. Natural evolution of regurgitation in healthy infants. *Acta Paediatr*. 2009;98(7):1189–1193

Variations in Definitions and Outcome Measures in Gastroesophageal Reflux Disease: A Systematic Review

Maartje M.J. Singendonk, Anna J. Brink, Nina F. Steutel, Faridi S. van Etten-Jamaludin, Michiel P. van Wijk, Marc A. Benninga and Merit M. Tabbers
Pediatrics 2017;140;

DOI: 10.1542/peds.2016-4166 originally published online July 27, 2017;

Updated Information & Services

including high resolution figures, can be found at:
<http://pediatrics.aappublications.org/content/140/2/e20164166>

References

This article cites 76 articles, 8 of which you can access for free at:
<http://pediatrics.aappublications.org/content/140/2/e20164166#BIBL>

Subspecialty Collections

This article, along with others on similar topics, appears in the following collection(s):
Gastroenterology
http://www.aappublications.org/cgi/collection/gastroenterology_sub

Permissions & Licensing

Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
<http://www.aappublications.org/site/misc/Permissions.xhtml>

Reprints

Information about ordering reprints can be found online:
<http://www.aappublications.org/site/misc/reprints.xhtml>

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN®



PEDIATRICS®

OFFICIAL JOURNAL OF THE AMERICAN ACADEMY OF PEDIATRICS

Variations in Definitions and Outcome Measures in Gastroesophageal Reflux Disease: A Systematic Review

Maartje M.J. Singendonk, Anna J. Brink, Nina F. Steutel, Faridi S. van Etten-Jamaludin, Michiel P. van Wijk, Marc A. Benninga and Merit M. Tabbers
Pediatrics 2017;140;

DOI: 10.1542/peds.2016-4166 originally published online July 27, 2017;

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://pediatrics.aappublications.org/content/140/2/e20164166>

Data Supplement at:

<http://pediatrics.aappublications.org/content/suppl/2017/07/19/peds.2016-4166.DCSupplemental>

Pediatrics is the official journal of the American Academy of Pediatrics. A monthly publication, it has been published continuously since 1948. Pediatrics is owned, published, and trademarked by the American Academy of Pediatrics, 345 Park Avenue, Itasca, Illinois, 60143. Copyright © 2017 by the American Academy of Pediatrics. All rights reserved. Print ISSN: 1073-0397.

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN®

